Esbloc

Esbloc Use In Pregnancy & Lactation

esmolol

Manufacturer:

Myungmoon

Distributor:

Masu
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: US Pregnancy Category C.
Teratogenicity studies in rats at intravenous dosages of Esmolol HCl up to 3000 micrograms/kg/min (3 milligrams/kg/min) (ten times the maximum human maintenance dosage) for 30 minutes daily produced no evidence of maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 micrograms/kg/min (1 milligrams/kg/min) for 30 minutes daily produced no evidence of maternal toxicity and lethality. In rabbits, intravenous dosages up to 1000 micrgrams/kg/min (1 milligrams/kg/min) for 30 minutes daily produced no evidence of maternal toxicity, embryotoxicity or teratogenicity, while 2500 micrograms/kg/min (2.5 milligrams/kg/min) produced minimal maternal toxicity and increased fetal resorptions.
Although there are no adequate and well-controlled studies in pregnant women, use of esmolol in the last trimester of pregnancy or during labor or delivery has been reported to cause fetal bradycardia, which continued after termination of drug infusion. Esmolol HCl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether Esmolol HCl is excreted in human; however, caution should be exercised when Esmolol HCl is administered to a nursing woman.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in